In this edition, sozinibercept combination therapy shows durability, comparable improvements with aflibercept and more.

Read the full coverage here:

Sozinibercept combination therapy shows durability in patients with DME, neovascular AMD

VIDEO: Comparable improvements seen with aflibercept 8 mg vs. 2 mg in DME

DPP-IV, SGLT2 and GLP-1 drugs do not increase risk for diabetic macular edema

Eluminex doses first patient in phase 1b trial of EB-105 for diabetic macular edema

VIDEO: Port delivery system maintains visual, anatomic improvements in DME at 2 years

References:

Awh C. Port delivery system with ranibizumab for continuous treatment of diabetic macular edema: First readout of the phase 3 Pagoda trial year 2 results. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.

Do D. Outcomes of patients with DME and baseline BCVA of 20/50 or worse or 20/40 or better treated with aflibercept 8 mg and 2 mg in the phase 2/3 PHOTON trial. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.

Phu A, et al. J Diabetes Complications. 2024;doi:10.1016/j.jdiacomp.2024.108808.

Press Release

Steinle NC. Durability of combination therapy of sozinibercept (OPT-302), an anti-VEGF-C/-D ‘trap’ with ranibizumab in nAMD or aflibercept in DME. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.